Sophea Sann Rorth
About Sophea Sann Rorth
Sophea Sann Rorth is a Senior Research Associate at LifeMine Therapeutics in Cambridge, MA, where she has worked since 2019. She specializes in gene expression analysis using RT-qPCR and qPCR, and possesses expertise in automated liquid handling and process development.
Work at LifeMine Therapeutics
Sophea Sann Rorth has served as a Senior Research Associate at LifeMine Therapeutics since 2019. In this role, she is involved in various molecular biology techniques, including running RT-qPCR and qPCR to assess gene expressions. She also assists in Gibson Assembly and the generation of new constructs, contributing to the Synthetic Biology group. Her focus on continuous process improvement enhances the efficiency and effectiveness of the research operations at the company, which is based in Cambridge, MA.
Previous Experience at Beckman Coulter
Before joining LifeMine Therapeutics, Sophea worked at Beckman Coulter as a Production Scientist III from 2007 to 2012. During her five years at the company, located in Danvers, MA, she developed her skills in automated liquid handlers and process development. This experience provided her with a solid foundation in scientific production processes and quality control.
Education and Expertise
Sophea Sann Rorth earned her Bachelor of Science (B.S.) degree in Chemistry Management from Simmons University, where she studied from 2001 to 2006. Her academic background has equipped her with a strong understanding of chemical processes and management principles. She possesses expertise in performing RNA, gDNA, and plasmid extractions, which are essential techniques in molecular biology and synthetic biology.
Technical Skills and Specializations
Sophea has developed strong technical skills in automated liquid handling and process development throughout her career. Her proficiency in running RT-qPCR and qPCR assays allows her to effectively evaluate gene expression levels. Additionally, her experience with RNA, gDNA, and plasmid extractions supports her contributions to research projects within the Synthetic Biology group at LifeMine Therapeutics.